Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Cash: 2012-2025

Historic Change in Cash for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$12.5 million.

  • Enanta Pharmaceuticals' Change in Cash fell 958.30% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year increase of 88.49%. This contributed to the annual value of -$5.5 million for FY2025, which is 88.49% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Change in Cash of -$12.5 million as of Q3 2025, which was up 18.75% from -$15.4 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Change in Cash peaked at $52.6 million during Q3 2021, and registered a low of -$72.5 million during Q2 2021.
  • Its 3-year average for Change in Cash is -$957,545, with a median of -$9.8 million in 2023.
  • In the last 5 years, Enanta Pharmaceuticals' Change in Cash skyrocketed by 513.43% in 2021 and then tumbled by 2,466.63% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Change in Cash (Quarterly) stood at $41.9 million in 2021, then crashed by 104.23% to -$1.8 million in 2022, then tumbled by 2,466.63% to -$45.5 million in 2023, then spiked by 203.65% to $47.1 million in 2024, then slumped by 958.30% to -$12.5 million in 2025.
  • Its Change in Cash was -$12.5 million in Q3 2025, compared to -$15.4 million in Q2 2025 and -$24.7 million in Q1 2025.